Best Small Cap Stocks To Watch For 2018

Small cap hair loss stocks Aclaris Therapeutics (NASDAQ: ACRS), Cytori Therapeutics (NASDAQ: CYTX) and RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) are trying to tap into a big market as currently, there are only two FDA-approved drugs available for the treatment of Androgenetic Alopecia (AGA) -also known as male or female pattern baldness (one of which cannot be used by women). Thus, a significant unmet need exists for a safe andefficacious product especially since its experienced by 70% of men and 40% of women as they age.

Right now, hairloss sufferers generally try Minoxidil (aka Rogaine), whichwas developed in the late 1950s by the Upjohn Company (later became part of Pfizer); orPropecia, which is manufactured by the pharmaceuticalgiant Merck & Co (NYSE: MRK). However, there are other treatments in the pipeline being advanced by big and small cap pharma or biotech stocks. For example: In 2015, large cap Allergan plc (NYSE: AGN) acquired small cap Kythera Biopharmaceuticals for $2.1 billion to add treatments for double chins and male pattern baldness. By acquiring Kythera, Allergangained aone-two punch for treating hair loss as italso has Bimatoprost (originally an eye treatment)in the pipeline as a topical hair growth treatment after it was found to lengthen and thicken womens eyelashes.

Best Small Cap Stocks To Watch For 2018: Achillion Pharmaceuticals Inc.(ACHN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    We updated our annual U.S. Hep C survey in early July, in order to gauge the future for Gilead, AbbVie/Enanta Pharmaceuticals (ENTA), Merck, and J&J/Achillion Pharmaceuticals (ACHN). In conjunction with script trends, physicians indicate that the market for treatment-eligible, easily accessible Hep C patients is shrinking, but that Gilead’s share of the shrinking pie is continuing to grow. With no end to script declines in sight, we are left wondering where the Hep C will bottom…

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Paul Ausick]

    Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) dropped about 6.9% Friday to post a new 52-week low of $2.69 after closing at $2.89 on Thursday. The 52-week high is $5.66. Volume was around 6.2 million, more than three times the daily average of around 1.9 million. The company had no specific news.

  • [By Ethan Ryder]

    Achillion Pharmaceuticals (NASDAQ:ACHN) – Research analysts at B. Riley reduced their FY2018 EPS estimates for shares of Achillion Pharmaceuticals in a research note issued to investors on Wednesday, May 2nd. B. Riley analyst M. Kumar now anticipates that the biopharmaceutical company will earn ($0.58) per share for the year, down from their previous estimate of ($0.55). B. Riley has a “Neutral” rating and a $3.50 price objective on the stock. B. Riley also issued estimates for Achillion Pharmaceuticals’ FY2019 earnings at ($0.64) EPS, FY2020 earnings at ($0.71) EPS, FY2021 earnings at ($0.70) EPS and FY2022 earnings at ($0.84) EPS.

Best Small Cap Stocks To Watch For 2018: FuelCell Energy Inc.(FCEL)

Advisors’ Opinion:

  • [By Shane Hupp]

    FuelCell Energy (NASDAQ: FCEL) is one of 25 public companies in the “Miscellaneous electrical machinery, equipment, & supplies” industry, but how does it contrast to its peers? We will compare FuelCell Energy to related companies based on the strength of its risk, dividends, earnings, valuation, profitability, analyst recommendations and institutional ownership.

  • [By Peter Graham]

    Small cap fuel cell stockFuelCell Energy Inc (NASDAQ: FCEL) reported Q4 and fiscal year ended October 31, 2017 earningswithQ4 total revenuesbeing $47.9 million versus $24.5 million:

  • [By Peter Graham]

    Small cap fuel cell stockFuelCell Energy Inc (NASDAQ: FCEL) reportedQ2 2017 earnings before the market opened with shares up in premarket trading. Total revenueswere $20.4 million versus $28.6 million with the revenue components being:

Best Small Cap Stocks To Watch For 2018: Rackspace Hosting Inc(RAX)

Advisors’ Opinion:

  • [By Monica Gerson]

    Rackspace Hosting, Inc. (NYSE: RAX) reported better-than-expected earnings for the first quarter, but the company missed analysts’ sales estimates. Rackspace shares dropped 7.72 percent to $20.80 in the after-hours trading session.

Best Small Cap Stocks To Watch For 2018: China Metro-Rural Holdings Limited(CNR)

Advisors’ Opinion:

  • [By Shane Hupp]

    Wall Street analysts expect that Canadian National Railway (NYSE:CNI) (TSE:CNR) will announce $1.02 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Canadian National Railway’s earnings, with the highest EPS estimate coming in at $1.06 and the lowest estimate coming in at $0.97. Canadian National Railway reported earnings per share of $1.00 in the same quarter last year, which would suggest a positive year over year growth rate of 2%. The company is expected to announce its next quarterly earnings results on Tuesday, July 24th.

  • [By Max Byerly]

    Canadian National Railway (NYSE:CNI) (TSE:CNR) – Cormark raised their Q3 2018 earnings per share (EPS) estimates for Canadian National Railway in a research report issued to clients and investors on Tuesday, April 10th. Cormark analyst D. Tyerman now expects that the transportation company will post earnings per share of $1.15 for the quarter, up from their previous estimate of $1.14.

Best Small Cap Stocks To Watch For 2018: Panera Bread Company(PNRA)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    In this segment fromMarket Foolery, host Chris Hill is joined by Motley Fool analystDavid Kretzmann as they break down how coffee-and-pastry focused JAB Holding Company will fit a fast casual brand into its privately held portfolio. With the acquisition, the JAB is expected to give thePanera Bread(NASDAQ:PNRA)team even more autonomy than usual.

  • [By Billy Duberstein]

    In late March, the company informed investors that after a two-year undertaking, it had finally removed all preservatives from its tortillas, making the Chipotle menu completely preservative-free. The company also called out competitors McDonald’s (NYSE: MCD) and Panera Bread (NASDAQ: PNRA) for marketing their menus as “natural,” as Chipotle insisted these other restaurants still use preservatives made in a lab.

  • [By WWW.THESTREET.COM]

    Cramer wanted to talk a little psychology. With its after-hours move Tuesday, Panera Bread (PNRA) is up more than 16% this week on takeover speculation. Panera is an old Action Alerts PLUS name, one the trust sold at a nice gain, too. 

  • [By Lisa Levin]

    Shares of Panera Bread Co (NASDAQ: PNRA) got a boost, shooting up 14 percent to $312.29 after the company agreed to be acquired by JAB for $7.5 billion.